Anebulo Pharmaceuticals Inc (ANEB)

Name: Anebulo Pharmaceuticals Inc Financial Statements
Creator: Quarter Results

Healthcare | Biotechnology

Latest reporting period: 2025-09-30

Latest Quarter

2025-09-30

Revenue

$0.0

Net Income

-$2.2M

Operating Margin

N/A

Free Cash Flow

-$6.3M

Debt / Assets

4.0%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Anebulo Pharmaceuticals Inc (ANEB).
Income Statement (Quarterly)	2025-09-30	2025-03-31	2024-12-31	2024-09-30
Revenue	0	0	0	0
Cost of Revenue	0	0	0	0
Gross Profit	0	0	0	0
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	1,450,269	1,254,000	1,368,000	1,097,000
Operating Expenses	2,260,260	1,892,000	2,588,000	2,412,000
Operating Income	-2,260,260	-1,892,000	-2,588,000	-2,412,000
Interest Expense	17,439	245,182	59,696	59,697
Income Before Tax	-2,158,354	-1,676,000	-2,463,000	-2,201,000
Income Tax Expense	0	0	0	0
Net Income	-2,158,354	-1,676,000	-2,463,000	-2,201,000
Per Share
EPS	-0.05	-0.04	-0.09	-0.08
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for Anebulo Pharmaceuticals Inc (ANEB).
Income Statement (Annual)	2025-06-30	2024-06-30	2023-06-30	2022-06-30	2021-06-30
Revenue	0	0	0	0	0
Cost of Revenue	0	0	0	0	0
Gross Profit	0	0	0	0	0
Operating Expenses
R&D Expenses	0	0	0	0	0
SG&A Expenses	4,923,540	4,760,000	6,183,000	3,869,636	1,343,755
Operating Expenses	9,223,481	8,309,000	11,784,000	6,831,174	3,613,753
Operating Income	-9,223,481	-8,309,000	-11,784,000	-6,831,174	-3,613,753
Interest Expense	382,014	151,230	0	7,332	11,767
Income Before Tax	-8,484,763	-8,202,000	-11,732,000	-6,825,619	-30,252,554
Income Tax Expense	0	0	-104,000	-12,887	0
Net Income	-8,484,763	-8,202,000	-11,732,000	-6,812,732	-30,252,554
Per Share
EPS	-0.25	-0.32	-0.47	-0.29	-2.83
EPS Diluted	0.00	0.00	0.00	0.00	0.00

Balance sheet quarterly history for Anebulo Pharmaceuticals Inc (ANEB).
Balance Sheet (Quarterly)	2025-06-30	2024-06-30	2023-06-30	2022-06-30
Assets
Cash and Cash Equivalents	11,627,849	3,094,200	11,247,403	14,548,471
Short Term Investments	0	0	0	0
Net Receivables	73,218	0	0	0
Inventory	0	0	0	0
Total Current Assets	11,962,506	3,507,990	11,247,403	14,548,471
Property Plant Equipment	0	0	0	0
Goodwill and Intangibles	0	0	0	0
Total Assets	12,145,616	4,073,114	11,670,151	15,579,431
Liabilities
Account Payables	224,175	156,426	534,545	380,828
Short Term Debt	0	0	0	0
Total Current Liabilities	224,175	260,583	534,545	512,531
Long Term Debt	0	0	0	0
Total Liabilities	487,688	260,583	1,068,801	512,531
Shareholders Equity
Retained Earnings	-73,888,507	-65,403,744	-57,202,041	-45,469,703
Total Shareholders Equity	11,657,928	3,812,531	10,601,350	15,066,900

Balance sheet annual history for Anebulo Pharmaceuticals Inc (ANEB).
Balance Sheet (Annual)	2025-06-30	2024-06-30	2023-06-30	2022-06-30	2021-06-30
Assets
Cash and Cash Equivalents	11,627,849	3,094,200	11,247,403	14,548,471	19,985,645
Short Term Investments	0	0	0	0	0
Net Receivables	73,218	0	0	0	0
Inventory	0	0	0	0	0
Total Current Assets	11,962,506	3,507,990	11,247,403	14,548,471	21,653,491
Property Plant Equipment	0	0	0	0	0
Goodwill and Intangibles	0	0	0	0	0
Total Assets	12,145,616	4,073,114	11,670,151	15,579,431	21,653,491
Liabilities
Account Payables	224,175	156,426	534,545	380,828	110,048
Short Term Debt	0	0	0	0	0
Total Current Liabilities	224,175	260,583	534,545	512,531	241,633
Long Term Debt	0	0	0	0	0
Total Liabilities	487,688	260,583	1,068,801	512,531	241,633
Shareholders Equity
Retained Earnings	-73,888,507	-65,403,744	-57,202,041	-45,469,703	-38,644,084
Total Shareholders Equity	11,657,928	3,812,531	10,601,350	15,066,900	21,411,858

Cash flow quarterly history for Anebulo Pharmaceuticals Inc (ANEB).
Cash Flow Statement (Quarterly)	2025-06-30	2024-06-30	2023-06-30	2022-06-30
Operating Activities
Net Income	-8,484,763	-8,201,703	-11,732,338	-6,825,619
Depreciation & Amortization	382,014	0	0	0
Stock Based Compensation	1,446,824	758,884	884,723	480,661
Change in Working Capital	306,238	-799,260	1,164,482	907,784
Operating Cash Flow	-6,349,687	-8,090,849	-9,683,133	-5,437,174
Investing Activities
Capital Expenditure	-3	0	0	0
Investments	0	0	0	0
Investing Cash Flow	0	0	0	0
Financing Activities
Debt Repayment	0	0	0	0
Common Stock Issued/Repurchased	14,883,336	654,000	6,646,748	0
Dividends Paid	0	0	0	0
Financing Cash Flow	14,883,336	-62,354	6,382,065	0
Summary
Free Cash Flow	-6,349,687	-8,090,849	-9,683,133	-5,437,174
Net Change in Cash	8,533,649	-8,153,203	-3,301,068	-5,437,174

Cash flow annual history for Anebulo Pharmaceuticals Inc (ANEB).
Cash Flow Statement (Annual)	2025-06-30	2024-06-30	2023-06-30	2022-06-30	2021-06-30
Operating Activities
Net Income	-8,484,763	-8,201,703	-11,732,338	-6,825,619	-30,252,554
Depreciation & Amortization	382,014	0	0	0	0
Stock Based Compensation	1,446,824	758,884	884,723	480,661	199,947
Change in Working Capital	306,238	-799,260	1,164,482	907,784	-1,445,292
Operating Cash Flow	-6,349,687	-8,090,849	-9,683,133	-5,437,174	-4,871,189
Investing Activities
Capital Expenditure	-3	0	0	0	0
Investments	0	0	0	0	0
Investing Cash Flow	0	0	0	0	0
Financing Activities
Debt Repayment	0	0	0	0	-201,286
Common Stock Issued/Repurchased	14,883,336	654,000	6,646,748	0	22,854,770
Dividends Paid	0	0	0	0	0
Financing Cash Flow	14,883,336	-62,354	6,382,065	0	21,831,854
Summary
Free Cash Flow	-6,349,687	-8,090,849	-9,683,133	-5,437,174	-4,871,189
Net Change in Cash	8,533,649	-8,153,203	-3,301,068	-5,437,174	16,960,665